Results from a mouse study of nonalcoholic steatohepatitis were promising for Viking Therapeutics' oral therapy VK2809, now also in a Phase 2 trial.
Fatty liver disease
FATTY LIVER DISEASE
NewsAlbireo Wins 2 U.S. Patents for A4250 Therapy to Treat NASH, Other Liver Diseases
Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis…
FATTY LIVER DISEASE
NewsMonkey Studies Prove Safety, Tolerability of IVA337 Experimental Therapy for Non-alcoholic Steatohepatitis
Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has shown a good safety profile in…
FATTY LIVER DISEASE
NewsEarly Study to Test Bioelectronic Treatment for NASH Inflammation
A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced.
FATTY LIVER DISEASE
NewsExposure to High-Fat Diet in Womb and During Breastfeeding Linked to Liver Disease
A child exposed to a mother’s high-fat diet while in the womb and breastfeeding is at greater risk of developing non-alcoholic fatty liver disease (NAFLD)…
Recent Posts
- Putting out the fires of inflammation in liver disease
- Change is good, but in life with MASH, it’s important to start small
- It turns out that having great friends is good for my health
- With Alagille syndrome, summer fun comes with a summer caution
- Gene therapy shows early promise for fatal childhood liver disease